Cargando…

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children

OBJECTIVE: To evaluate the clinical efficacy and safety of a short course of blinatumomab in children with refractory or relapsed precursor B-cell acute lymphoblastic leukemia (R/R-BCP-ALL). METHODS: The clinical data of 33 R/R BCP-ALL children aged 0–18 years who underwent a short course of blinatu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xie, Jiao, Liu, Suxiang, Zhou, Ming, Wang, Yi, He, Hailong, Xiao, Peifang, Hu, Shaoyan, Lu, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437063/ https://www.ncbi.nlm.nih.gov/pubmed/37601130 http://dx.doi.org/10.3389/fped.2023.1187607

Ejemplares similares

Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia
por: Topp, M S, et al.
Publicado: (2018)

Immunotargeting relapsed or refractory precursor B-cell acute lymphoblastic leukemia – role of blinatumomab
por: Queudeville, Manon, et al.
Publicado: (2017)

FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B‐Cell Acute Lymphoblastic Leukemia
por: Pulte, E. Dianne, et al.
Publicado: (2018)

Benefit–Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Stein, Anthony, et al.
Publicado: (2018)

Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study
por: Wang, Songmi, et al.
Publicado: (2023)

Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
por: Gore, Lia, et al.
Publicado: (2018)

Profile of blinatumomab and its potential in the treatment of relapsed/refractory acute lymphoblastic leukemia
por: Ribera, Josep-Maria, et al.
Publicado: (2015)

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Kantarjian, Hagop M., et al.
Publicado: (2021)

Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia
por: Gökbuget, N, et al.
Publicado: (2016)

Impact of blinatumomab on patient outcomes in relapsed/refractory acute lymphoblastic leukemia: evidence to date
por: Hathaway, Lindsey, et al.
Publicado: (2018)

Long‐term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
por: Topp, Max S., et al.
Publicado: (2020)

Immunophenotypic changes of leukemic blasts in children with relapsed/refractory B-cell precursor acute lymphoblastic leukemia who have been treated with blinatumomab
por: Mikhailova, Ekaterina, et al.
Publicado: (2020)

Comment on 'Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia'
por: Tong, W H
Publicado: (2016)

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Proskorovsky, Irina, et al.
Publicado: (2019)

Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia
por: Locatelli, Franco, et al.
Publicado: (2020)

Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome–positive B‐precursor acute lymphoblastic leukemia
por: Rambaldi, Alessandro, et al.
Publicado: (2019)

Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia
por: Kobayashi, Yukio, et al.
Publicado: (2021)

The safety of blinatumomab in pediatric patients with acute lymphoblastic leukemia: A systematic review and meta-analysis
por: Marrapodi, Maria Maddalena, et al.
Publicado: (2022)

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Song, Jinlin, et al.
Publicado: (2019)

Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study
por: Wu, Ying, et al.
Publicado: (2022)

Cost Effectiveness of Blinatumomab Versus Inotuzumab Ozogamicin in Adult Patients with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia in the United States
por: Delea, Thomas E., et al.
Publicado: (2019)

Phase 1b/2 study of blinatumomab in Japanese adults with relapsed/refractory acute lymphoblastic leukemia
por: Kiyoi, Hitoshi, et al.
Publicado: (2020)

Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Ueda, Tomoaki, et al.
Publicado: (2022)

CD19-negative relapse of pediatric B-cell precursor acute lymphoblastic leukemia following blinatumomab treatment
por: Mejstríková, E., et al.
Publicado: (2017)

Corrigendum: Blinatumomab for treating pediatric B-lineage acute lymphoblastic leukemia: A retrospective real-world study
por: Wu, Ying, et al.
Publicado: (2022)

Real-World Multicenter Experience in Tumor Debulking Prior to Blinatumomab Administration in Adult Patients With Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
por: Bonifacio, Massimiliano, et al.
Publicado: (2022)

Targeted Treatment and Immunotherapy in High-risk and Relapsed/Refractory Pediatric Acute Lymphoblastic Leukemia
por: Graiqevci-Uka, Violeta, et al.
Publicado: (2022)

Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors
por: Stein, Anthony S., et al.
Publicado: (2018)

Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
por: Locatelli, Franco, et al.
Publicado: (2020)

Blinatumomab as a Bridge Therapy for Hematopoietic Stem Cell Transplantation in Pediatric Refractory/Relapsed Acute Lymphoblastic Leukemia
por: Pawinska-Wasikowska, Katarzyna, et al.
Publicado: (2022)

Survival outcomes in patients with relapsed/refractory or MRD-positive B-cell acute lymphoblastic leukemia treated with blinatumomab
por: Kantarjian, Hagop M., et al.
Publicado: (2023)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Estimating Long-Term Survival of Adults with Philadelphia Chromosome-Negative Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia Treated with Blinatumomab Using Historical Data
por: Barlev, Arie, et al.
Publicado: (2016)

Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B‐cell precursor acute lymphoblastic leukemia: Results of a pooled analysis
por: Topp, Max S., et al.
Publicado: (2021)

Testicular relapse of acute lymphoblastic leukemia()
por: Carolan, Alexandra, et al.
Publicado: (2023)

Efficacy and safety of blinatumomab in children with relapsed/refractory B cell acute lymphoblastic leukemia: A systematic review and meta-analysis
por: Chen, Bin, et al.
Publicado: (2023)

Correction: Blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study
por: Locatelli, Franco, et al.
Publicado: (2021)

Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
por: Locatelli, Franco, et al.
Publicado: (2022)

Cost-Effectiveness of Blinatumomab in Pediatric Patients with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia in France
por: Caillon, Megane, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_9daipf4t79ohoe7ijmcp8k9lir